MRI-based response patterns during neoadjuvant chemotherapy can predict pathological (complete) response in patients with breast cancer

被引:51
|
作者
Goorts, Briete X. Z. [1 ,2 ,3 ]
Dreuning, Kelly M. A. [2 ]
Houwers, Janneke B. [3 ]
Kooreman, Loes F. S. [1 ,4 ]
Boerma, Evert-Jan G. [5 ]
Mann, Ritse M. [6 ]
Lobbes, Marc B. I. [1 ,3 ]
Smidt, Marjolein L. [1 ,2 ]
机构
[1] Maastricht Univ, Med Ctr, GROW Sch Oncol & Dev Biol, Maastricht, Netherlands
[2] Maastricht Univ, Med Ctr, Dept Surg, Maastricht, Netherlands
[3] Maastricht Univ, Med Ctr, Dept Radiol & Nucl Med, POB 5800, NL-6202 AZ Maastricht, Netherlands
[4] Maastricht Univ, Med Ctr, Dept Pathol, Maastricht, Netherlands
[5] Zuyderland Med Ctr, Dept Surg, Sittard Geleen, Netherlands
[6] Radboud Univ Nijmegen, Med Ctr, Dept Radiol & Nucl Med, Nijmegen, Netherlands
来源
BREAST CANCER RESEARCH | 2018年 / 20卷
关键词
Breast Cancer; Neoadjuvant chemotherapy; Magnetic resonance imaging; RECOMMENDATIONS; THERAPY; UPDATE; TRIAL;
D O I
10.1186/s13058-018-0950-x
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: The main purpose was to investigate the correlation between magnetic resonance imaging (MRI)-based response patterns halfway through neoadjuvant chemotherapy and immunotherapy (NAC) and pathological tumor response in patients with breast cancer. Secondary purposes were to compare the predictive value of MRI-based response patterns measured halfway through NAC and after NAC and to measure interobserver variability.& para;& para;Methods: All consecutive patients treated with NAC for primary invasive breast cancer from 2012 to 2015 and who underwent breast MRI before, halfway through (and after) NAC were included. All breast tumors were reassessed on MRI by two experienced breast radiologists and classified into six patterns: type 0 (complete radiologic response); type 1 (concentric shrinkage); type 2 (crumbling); type 3 (diffuse enhancement); type 4 (stable disease); type 5 (progressive disease). Percentages of tumors showing pathological complete response (pCR), > 50% tumor reduction and > 50% tumor diameter reduction per MRI-based response pattern were calculated. Correlation between MRI-based response patterns and pathological tumor reduction was studied with Pearson's correlation coefficient, and interobserver agreement was tested with Cohen's Kappa.& para;& para;Results: Patients (n = 76; mean age 53, range 29-72 years) with 80 tumors (4 bilateral) were included. There was significant correlation between these MRI-based response patterns halfway through NAC and tumor reduction on pathology assessment (reader 1 r = 0.33; p = 0.003 and reader 2 r = 0.45; p < 0.001). Type-0, type-1 or type-2 patterns halfway through NAC showed highest tumor reduction rates on pathology assessment, with > 50% tumor reduction in 90%, 78% and 65% of cases, respectively. In 83% of tumors with type 0 halfway through NAC, pathology assessment showed pCR. There was no significant correlation between MRI-based response patterns after NAC and tumor reduction rates on pathology assessment (reader 1 r = - 0.17; p = 0.145 and reader 2 r = - 0.17; p = 0.146). In 41% of tumors with type 0 after NAC, pathology assessment showed pCR.& para;& para;Conclusion: MRI-based response patterns halfway through NAC can predict pathologic response more accurately than MRI-based response patterns after NAC. Complete radiological response halfway NAC is associated with 83% pCR, while complete radiological response after NAC seems to be correct in only 41% of cases.
引用
收藏
页数:10
相关论文
共 50 条
  • [41] Prediction of pathological complete response to neoadjuvant chemotherapy by magnetic resonance imaging in breast cancer patients
    Michishita, Shintaro
    Kim, Seung Jin
    Shimazu, Kenzo
    Sota, Yoshiaki
    Naoi, Yasuto
    Maruyama, Naomi
    Kagara, Naofumi
    Shimoda, Masafumi
    Shimomura, Atsushi
    Noguchi, Shinzaburo
    BREAST, 2015, 24 (02): : 159 - 165
  • [42] Recurrence and survival among breast cancer patients achieving a pathological complete response to neoadjuvant chemotherapy
    Chaudry, Misbat
    Lei, Xiudong
    Gonzalez-Angulo, Ana M.
    Mittendorf, Elizabeth A.
    Valero, Vicente
    Tripathy, Debu
    Hortobagyi, Gabriel N.
    Chavez-MacGregor, Mariana
    BREAST CANCER RESEARCH AND TREATMENT, 2015, 153 (02) : 417 - 423
  • [43] Recurrence and survival among breast cancer patients achieving a pathological complete response to neoadjuvant chemotherapy
    Misbat Chaudry
    Xiudong Lei
    Ana M. Gonzalez-Angulo
    Elizabeth A. Mittendorf
    Vicente Valero
    Debu Tripathy
    Gabriel N. Hortobagyi
    Mariana Chavez-MacGregor
    Breast Cancer Research and Treatment, 2015, 153 : 417 - 423
  • [44] Correlation on metabolic complete response on positron emission tomography and pathological complete response in patients with breast cancer after neoadjuvant chemotherapy
    Ma, Lorraine Wai Yan
    Cheung, Polly Suk Yee
    Ho, Chi Lai
    Wong, Yuet Hung
    Luk, Wing Pan
    Fung, Ling Hiu
    WORLD JOURNAL OF SURGERY, 2025,
  • [45] Predictive factors of pathological complete response by neoadjuvant chemotherapy for operable breast cancer
    Ishikawa, Takashi
    Shimizu, Daisuke
    Sasaki, Takashi
    Morita, Satoshi
    Tanabe, Mikiko
    Ota, Ikuko
    Kawachi, Kae
    Chishima, Takashi
    Ichikawa, Yasushi
    Endo, Itaru
    CANCER RESEARCH, 2011, 71
  • [46] Improving pathological complete response in luminal breast cancer after neoadjuvant chemotherapy
    Cudos, Ariadna Gasol
    Murillo, Serafin Morales
    Galindo, Alvaro Rodriguez
    Subirats, Ona Pallise
    Olive, Jordi Mele
    Morales, Carles Canosa
    Villellas, Felip Vilardell
    Guzman, Douglas Rene Sanchez
    Rodriguez, Joel Veas
    CANCER RESEARCH, 2022, 82 (04)
  • [47] Complete pathological response to neoadjuvant chemotherapy and its impact on breast cancer outcomes
    Boudaouara, O.
    Ben Makhlouf, W.
    Bouhamed, M.
    Graja, S.
    Charfi, S.
    Boudawara, T. Sellami
    Ben Kridis, W.
    VIRCHOWS ARCHIV, 2024, 485 : S189 - S189
  • [48] Factors predicting a pathological complete response following neoadjuvant chemotherapy for breast cancer
    Choi, H.
    Van Belle, V.
    Wildiers, H.
    Paridaens, R.
    Amant, F.
    Van Limbergen, E.
    Moerman, P.
    Smeets, A.
    Vergote, I.
    Neven, P.
    EJC SUPPLEMENTS, 2010, 8 (03): : 66 - 67
  • [49] Pathological complete response (pCR) after neoadjuvant chemotherapy in luminal breast cancer
    Cordoba Ortega, J. F.
    Gasol Cudos, A.
    Morales Murillo, S.
    Vilardell Villellas, F.
    Siso Raber, C.
    Canosa Morales, C.
    Salud Salvia, A.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S313 - S313
  • [50] Magnetic Resonance Imaging to predict pathological response neoadjuvant chemotherapy for breast cancer
    Lamot, C.
    Van fraeyenhove, F.
    Denys, H.
    Van Herreweghe, E.
    Van den Broecke, R.
    Villeirs, G.
    Depypere, H.
    Praet, M.
    Cocquyt, V.
    EJC SUPPLEMENTS, 2008, 6 (07): : 60 - 61